MX2022005912A - Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria. - Google Patents

Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.

Info

Publication number
MX2022005912A
MX2022005912A MX2022005912A MX2022005912A MX2022005912A MX 2022005912 A MX2022005912 A MX 2022005912A MX 2022005912 A MX2022005912 A MX 2022005912A MX 2022005912 A MX2022005912 A MX 2022005912A MX 2022005912 A MX2022005912 A MX 2022005912A
Authority
MX
Mexico
Prior art keywords
compounds
naphthyridin
treatment
autoimmune disease
diastereomer
Prior art date
Application number
MX2022005912A
Other languages
English (en)
Inventor
Hong Shen
Wei Zhu
Zhisen Zhang
Hongtao Xu
Ge Zou
Xiaoqing Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022005912A publication Critical patent/MX2022005912A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

La presente invención se refiere a compuestos de la Fórmula (I), (ver Fórmula) (I), en donde R1 a R3, m y n son como se describen en la presente, y su sal farmacéuticamente aceptable, un enantiómero o diastereómero de los mismos, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
MX2022005912A 2019-11-26 2020-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria. MX2022005912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120996 2019-11-26
PCT/EP2020/083113 WO2021105072A1 (en) 2019-11-26 2020-11-24 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
MX2022005912A true MX2022005912A (es) 2022-06-24

Family

ID=73598065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005912A MX2022005912A (es) 2019-11-26 2020-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.

Country Status (16)

Country Link
US (1) US20230041743A1 (es)
EP (1) EP4065586A1 (es)
JP (1) JP2023503165A (es)
KR (1) KR20220106126A (es)
CN (1) CN114728987A (es)
AR (1) AR120540A1 (es)
AU (1) AU2020393367A1 (es)
BR (1) BR112022009856A2 (es)
CA (1) CA3156457A1 (es)
CO (1) CO2022006942A2 (es)
CR (1) CR20220231A (es)
IL (1) IL291640A (es)
MX (1) MX2022005912A (es)
PE (1) PE20221026A1 (es)
TW (1) TW202134238A (es)
WO (1) WO2021105072A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
US9475813B2 (en) * 2013-02-08 2016-10-25 Nissan Chemical Industries, Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor
KR20180094939A (ko) * 2015-12-17 2018-08-24 메르크 파텐트 게엠베하 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
WO2018178041A1 (en) * 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
CN110831600B (zh) * 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途

Also Published As

Publication number Publication date
CR20220231A (es) 2022-06-27
PE20221026A1 (es) 2022-06-16
KR20220106126A (ko) 2022-07-28
IL291640A (en) 2022-05-01
CA3156457A1 (en) 2021-06-03
CO2022006942A2 (es) 2022-06-10
EP4065586A1 (en) 2022-10-05
TW202134238A (zh) 2021-09-16
JP2023503165A (ja) 2023-01-26
CN114728987A (zh) 2022-07-08
US20230041743A1 (en) 2023-02-09
BR112022009856A2 (pt) 2022-08-02
WO2021105072A1 (en) 2021-06-03
AR120540A1 (es) 2022-02-23
AU2020393367A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020007265A (es) Derivados de rapamicina.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
AU2018253590A1 (en) Imidazopyridazine compounds
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2021012105A (es) Compuestos de pirrol.
MX2022005522A (es) Formas de sal de un receptor de componente c5a de complemento.
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2020008413A (es) Composiciones para la prevencion o tratamiento de la uveitis.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
PH12020551620A1 (en) Compositions for preventing or treating dry eye